Wechselwirkungen · Emtricitabine/Tenofovir disoproxil Mylan
Emtricitabine/Tenofovir disoproxil Mylan 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-134216 · Präparat HOS-097542
13 Medicinal product by Effects on drug Recommendation concerning therapeutic areas levels co-administration with Mean percent emtricitabine/tenofovir disoproxil change in AUC, (emtricitabine 200 mg, tenofovir disoproxil Cmax, Cmin with 245 mg) 90% confidence intervals if available (mechanism) Hepatitis C virus (HCV) antiviral agents Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma concentrations of tenofovir (90 mg/400 mg q.d.) + AUC: ↑ 96% (↑ resulting from co-administration of tenofovir Atazanavir/Ritonavir 74 to ↑ 121) disoproxil, ledipasvir/sofosbuvir and (300 mg q.d. /100 mg q.d.) + Cmax: ↑ 68% (↑ 54 atazanavir/ritonavir may increase adverse Emtricitabine/Tenofovir disoproxil to ↑ 84) (200 mg/245 mg q.d.)1 reactions related to tenofovir disoproxil, Cmin: ↑ 118% (↑ including renal disorders. The safety of 91 to ↑ 150) tenofovir disoproxil when used with ledipasvir/sofosbuvir and a pharmacokinetic Sofosbuvir: enhancer (e.g. ritonavir or cobicistat) has not AUC: ↔ Cmax: ↔ been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) tenofovir disoproxil (HOS-108843) hepatitis C virus (HOS-108813) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-03T14:25:00Z · SHA-256 dca28001b5f37f5fac24ef504bb45938e413f238844fb60b012f3f9b5a32b40c · Passage 13ce8331ef62ab4a8ac7c9b0519f5abd9c5c25e38a0192fd040164ba19c2d894 · Zeichen 11107–12870 im Abschnitt